

RealRate

PHARMACEUTICAL 2020

ALIMERA SCIENCES INC Rank 84 of 358







RealRate

PHARMACEUTICAL 2020

ALIMERA SCIENCES INC Rank 84 of 358



The relative strengths and weaknesses of ALIMERA SCIENCES INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ALIMERA SCIENCES INC compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 129% points. The greatest weakness of ALIMERA SCIENCES INC is the variable Other Expenses, reducing the Economic Capital Ratio by 104% points.

The company's Economic Capital Ratio, given in the ranking table, is 177%, being 141% points above the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	32,745
Cost of Goods Sold	0
Intangible Assets	14,783
Liabilities, Current	12,048
Liabilities, Non-Current	0
Other Assets	2,781
Other Compr. Net Income	-82
Other Expenses	39,356
Other Liabilities	0
Other Net Income	-84
Other Revenues	53,943
Property and Equipment	0
Research and Development	10,992
Selling, General and Administrative Expense	13,954

Output Variable	Value in 1000 USD
Assets	50,309
Liabilities	12,048
Expenses	64,302
Revenues	53,943
Stockholders Equity	38,261
Net Income	-10,443
Comprehensive Net Income	-10,484
Economic Capital Ratio	177%

